Exploring the Therapeutic Potential of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Polycystic Ovary Syndrome.

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting women of reproductive age and is characterized by hormonal imbalances, insulin resistance, and reproductive dysfunctions. Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are primarily used in diabetes management to enhance insulin release by stimulating GLP-1 receptors in the pancreas. The search strategy included randomized trials on the management of PCOS symptoms with GLP-1 RAs alone or in combination with other medications; meta-analyses, literature reviews, or case reports were excluded.